CSA fine for J&J
This article was originally published in The Tan Sheet
Johnson & Johnson will pay $511,000 in fines because imports of pseudoephedrine-containingBenedryl-D to a manufacturing facility in Lititz, Pa., were not reported as required by the Controlled Substances Act, according to an Aug. 5 settlement with the Department of Justice. The U.S. Attorney's Office for the Eastern District of Pennsylvania and J&J subsidiary McNeil-PPC explain the unreported imports of the OTC nasal decongestant tablets occurred during 2001 to 2005, when Pfizer's Warner-Lambert business owned the facility. J&J acquired the facility in 2006 when it bought Pfizer Consumer Healthcare (1"The Tan Sheet" Dec. 18, 2006, p. 9). DOJ says the CSA requires companies to file reports with the Drug Enforcement Agency within 15 days of importing products containing pseudophedrine and other specified chemicals that can be used in manufacturing controlled substances...
You may also be interested in...
Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business
Despite increased pressures from inflation and dependence on international supply chains, the average cost of generics in Canada is 45% lower than in 11 comparator countries, the CGPA reports.
Teva’s innovative and generic interests can not only co-exist but are complementary, CEO Richard Francis has set out, in response to questions over whether the Israeli giant would consider splitting its businesses to focus more on branded drugs.